Tekmira Cleared to Begin Phase I Testing of Cancer Drug | GenomeWeb

Tekmira Pharmaceuticals said this week that it has received clearance from the US Food and Drug Administration to being phase I testing of the siRNA-based cancer drug TKM-PLK1.

"With this approval, we remain on track to achieve the company's milestone of initiating a phase I human clinical trial in patients with advanced solid tumors before the end of the year," Tekmira President and CEO Mark Murray said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.